☆ 4.3 Article

Thyroid dysfunction after immune checkpoint inhibitor treatment in a single-center Chinese cohort: a retrospective study

ENDOCRINE (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Oncology

Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario

Calogera Claudia Spagnolo et al.

Summary: Immune checkpoint inhibitors have revolutionized the treatment of solid tumors, but their use is associated with unique toxicities related to the enhancement of the immune response. This review provides a comprehensive overview of endocrine and metabolic adverse events of immune checkpoint inhibitors and summarizes the latest studies and recommendations on their clinical approach and management.

CANCERS (2023)

添加到收藏夹

Review Oncology

Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis

Yee-Ming Melody Cheung et al.

Summary: The development of immune-related thyroid dysfunction during immune checkpoint inhibitor therapy is associated with improved overall survival and progression free survival for cancer patients. This suggests that thyroid immune-related adverse events can be used as a surrogate marker for clinical response to ICIs.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline

Shintaro Iwama et al.

Summary: The study revealed that the incidence of thyroid immune-related adverse events was high after PD-1/CTLA-4-Abs treatment even in patients negative for ATAs at baseline.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

添加到收藏夹

Article Oncology

Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China

Yuequan Shi et al.

Summary: This study observed immune-related adverse events (irAEs) in 1905 patients with advanced lung cancer treated with ICIs, finding an incidence rate of 26.9%. The most common irAEs were thyroid dysfunction, pneumonitis, and dermatological toxicities. Patients who received first-line ICI treatment and had positive PD-L1 expression were more likely to develop irAEs, which may be associated with a better disease control rate.

THORACIC CANCER (2022)

添加到收藏夹

Review Rheumatology

Autoantibodies in Patients With Immune-Related Adverse Events From Checkpoint Inhibitors A Systematic Literature Review

Nilasha Ghosh et al.

Summary: Autoantibodies are sometimes associated with immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs), but their presence before ICI initiation and their frequency were not known. This study found that autoantibodies were present in close to 50% of patients with ICI-associated endocrinopathies and more than 50% of patients with skin irAEs. However, the positivity rate of autoantibodies was lower in irAEs affecting other organ systems. There are mixed results regarding the utility of autoantibodies as biomarkers of irAEs.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2022)

添加到收藏夹

Article Endocrinology & Metabolism

Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients

Han-Sang Baek et al.

Summary: Thyroid dysfunction caused by ICIs treatment is associated with better survival, especially for patients with newly developed overt or subclinical hypothyroidism.

BMC ENDOCRINE DISORDERS (2022)

添加到收藏夹

Review Oncology

Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias

Maria Kfoury et al.

Summary: This study conducted an observational study on real-life data of patients treated with immune checkpoint blockers for melanoma and non-small cell lung cancer, confirming the association between immune-related adverse events and improved survival using a time-varying Cox regression model.

CANCER TREATMENT REVIEWS (2022)

添加到收藏夹

Article Oncology

Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors

Joana Lima Ferreira et al.

Summary: Immune-checkpoint inhibitors can lead to thyroid function abnormalities, including primary and central hypothyroidism, which may be predictive of improved clinical outcomes and response to ICI treatment across different types of neoplasms.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology

Sabrina Hoa et al.

Summary: Limited data are available on the safety and efficacy of immune checkpoint inhibitors in patients with preexisting autoimmune diseases. A retrospective study in Canada found that exacerbations of preexisting autoimmune diseases were common in patients receiving ICI therapy, especially in those who had previously required more intensive immunosuppressive therapies. Flares may occur despite background immunosuppression and rheumatic immune-related adverse events were frequently observed in patients with preexisting psoriasis, IBD, and axial spondyloarthritis.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study

Philippe Thuillier et al.

Summary: This study suggested that TD induced by Nivolumab appears to be an independent predictive factor of survival, irrespective of TD severity and subtype.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors

Li Zhong et al.

Summary: This study demonstrates that irAEs triggered by ICIs, especially in the skin, endocrine organs, or gastrointestinal tract, can predict significant survival benefits for patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)

添加到收藏夹

Article Oncology

Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC

Nanruoyi Zhou et al.

Summary: Thyroid dysfunction is a common adverse event in NSCLC patients treated with ICI, with some cases occurring after treatment cessation. More investigation is needed to better understand the incidence and impact of post-treatment thyroid dysfunction in this patient population.

LUNG CANCER (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model

Silvia Ippolito et al.

Summary: The study compared thyroiditis induced by PD-1 and CTLA-4 blockade in a mouse model, revealing more severe inflammation with PD-1 blockade and more prevalent thyroiditis with larger thyroid area in the CTLA-4 group. Serum IL-6 significantly increased with PD-1 blockade, correlating with thyroiditis severity, while other cytokines did not differ significantly among the treatment groups.

THYROID (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Christopher A. Muir et al.

Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with different subtypes of thyroid immune-related adverse events having unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer progression free survival and overall survival, while hypothyroidism showed no association with cancer outcomes. Multiple distinct phenotypes of thyroid irAEs suggest potentially different etiologies for thyrotoxicosis and hypothyroidism.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Cell Biology

CD4+ T cells are essential for the development of destructive thyroiditis induced by anti-PD-1 antibody in thyroglobulin-immunized mice

Yoshinori Yasuda et al.

Summary: The study found that CD4(+) T cells play a critical role in the development of destructive thyroiditis, and depletion of CD4(+) T cells can completely prevent the occurrence of the disease.

SCIENCE TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Article Endocrinology & Metabolism

Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment

Christopher A. Muir et al.

Summary: Thyroid dysfunction is common following immune checkpoint inhibition, with distinct phenotypes of thyroid irAEs showing unique clinical and biochemical associations. Overt thyrotoxicosis was associated with longer survival outcomes, while no association was found between hypothyroidism and cancer outcomes.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)

添加到收藏夹

Article Oncology

Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors

Chiaki Kurimoto et al.

CANCER SCIENCE (2020)

添加到收藏夹

Article Endocrinology & Metabolism

PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients

Anupam Kotwal et al.

THYROID (2020)

添加到收藏夹

Article Endocrinology & Metabolism

Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer

Christopher A. Muir et al.

THYROID (2020)

添加到收藏夹

Review Immunology

Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation

Massimo Ralli et al.

AUTOIMMUNITY REVIEWS (2020)

添加到收藏夹

Article Endocrinology & Metabolism

BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION

Rena M. Pollack et al.

ENDOCRINE PRACTICE (2019)

添加到收藏夹

Article Multidisciplinary Sciences

Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab

Ichiro Yamauchi et al.

PLOS ONE (2019)

添加到收藏夹

Review Endocrinology & Metabolism

Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know)

R. M. Ruggeri et al.

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2019)

添加到收藏夹

Article Endocrinology & Metabolism

Nivolumab Induced Thyroid Dysfunction: Unusual Clinical Presentation and Challenging Diagnosis

Carmine Iadarola et al.

FRONTIERS IN ENDOCRINOLOGY (2019)

添加到收藏夹

Article Endocrinology & Metabolism

The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma

Emma S. Scott et al.

EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)

添加到收藏夹

Article Oncology

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Hye In Kim et al.

ONCOIMMUNOLOGY (2018)

添加到收藏夹

Article Oncology

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders

Katharina C. Kaehler et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)

添加到收藏夹

Editorial Material Immunology

Immune Checkpoint Blockade across the Cancer Care Continuum

Beth A. Helmink et al.

IMMUNITY (2018)

添加到收藏夹

Article Oncology

Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders

Giulia C. Leonardi et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small Cell Lung Cancer

Koji Haratani et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens A Systematic Review and Meta-analysis

Romualdo Barroso-Sousa et al.

JAMA ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab

Shiro Kimbara et al.

CANCER SCIENCE (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

Priyanka C. Iyer et al.

THYROID (2018)

添加到收藏夹

Article Endocrinology & Metabolism

Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study

Tomoko Kobayashi et al.

JOURNAL OF THE ENDOCRINE SOCIETY (2018)

添加到收藏夹

Article Oncology

Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer

J. C. Osorio et al.

ANNALS OF ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity

Ralf Gutzmer et al.

EUROPEAN JOURNAL OF CANCER (2017)

添加到收藏夹

Article Oncology

Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy

Hyunju Lee et al.

CANCER IMMUNOLOGY RESEARCH (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma

D. L. Morganstein et al.

CLINICAL ENDOCRINOLOGY (2017)

添加到收藏夹

Review Multidisciplinary Sciences

The future of immune checkpoint therapy

Padmanee Sharma et al.

SCIENCE (2015)

添加到收藏夹

Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.